Worldwide Market Reports

Chronic Idiopathic Constipation (CIC) Drugs Market: Regional Knowledge Analysis by Production, Margin of Profit and Prognosis Till 2027

Growing awareness and increasing incidence and prevalence of chronic idiopathic constipation - CIC are the major factors driving the CIC drugs market worldwide. Growth in demand for CIC drugs in Asia Pacific, coupled with the huge gap of unmet needs in the region is expected to serve as a significant opportunity in the global market during forecast period.


Seattle, WA -- (SBWIRE) -- 11/15/2019 -- Constipation can be defined as a condition with decreased stool frequency or issues in passing stool. Reduced or tough stool passage is accompanied by hard lumpy stools, incomplete bowel actions, straining, incomplete evacuation, and necessity for manual elimination of stool. Chronic Idiopathic Constipation (CIC) can be described as an additional, persistent or extreme continuation of the above-mentioned signs and symptoms. Several times, the cause of chronic idiopathic constipation is not known. Since the cause of constipation is uncertain, it is known as idiopathic constipation. Chronic idiopathic constipation Market is often indicated with more than one symptoms.

For More Info Get Free Sample Report Here:

Global Chronic Idiopathic Constipation (CIC) Drugs Market is estimated to reach US $ Million by 2027 Says, Worldwide Market Reports; growing at a CAGR of % between 2016 and 2027. Increasing awareness and widespread presence of idiopathic constipation are the key factors for growth of CIC drugs market. Currently CIC drugs market has huge opportunity for research and development.

Depending on type of drugs, global CIC drugs market is segmented into Lubiprostone, Linaclotide and others. Currently Lubiprostone drug segment dominates the market. But, due to its lower efficacy in comparison with others, patent loss and growing competition from Linaclotide, Lubiprostone will lose its dominance in the upcoming future. Depending on prescription types it is subdivided into prescribed drugs and over the counter drugs.

Based on drug class, the global chronic idiopathic constipation market can be segmented into emollients, laxatives, chloride channel activators, osmotic products, and others. The laxatives segment is likely to expand at a significant pace during the forecast period. The advantage of a laxative is that it can be generally sold over the counter and it can even be prescribed as the first line of treatment to relieve idiopathic constipation. Based on route of administration, the chronic idiopathic constipation market can be segmented into oral and parenteral. The oral segment is likely to expand at a rapid pace during the forecast period, as patients prefer taking oral drugs as they are convenient, invasive, and require no special training to take drugs.

North America dominates the global chronic idiopathic constipation market. The region is projected to hold a significant share of the global chronic idiopathic constipation market during the forecast period, due to increasing prevalence of chronic idiopathic constipation among the geriatric population in the region. On the other hand, high prevalence of functional constipation and increasing health care expenditure in Asia Pacific are expected to fuel the chronic idiopathic constipation market in the region during the forecast period. Advancements in drug delivery, increase in per capita income, and availability of generic drugs are likely to augment the chronic idiopathic constipation Market in Middle East & Africa during the forecast period.

After analysing the symptoms also, constipation is not considered as a disease but a condition, side effect or syndrome. Usually patients avoid to visit doctors to address the issue. Therefore approximately 65% of the CIC drugs market is covered by over the counter drugs. The top players of CIC drugs market are Actavis, Chugai Pharmaceutical, Ferring International Center S.A., Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding AG, Sanofi, Bayer AG, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc, Ironwood Pharmaceuticals and Progenics Pharmaceuticals.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Else, Place an Inquire before Purchase:

*If you have any special requirements, please let us know and we will offer you the report as you want.